个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP) ◇ 自然指数

作者：
Jin, Jie[1] * ; Wang, Huafeng[1] ; Yu, Wen-Juan[1] ; Ge, Zheng[2] ; Wei, Xudong[3] ; Li, Yuhua[4] ; Jiang, Zhongxing[5] ; Li, Yiqing[6] ; Du, Xin[7,22] ; Yang, Linhua[8] ; Lin, Lie[9] ; Wang, Jishi[10] ; Yao, Yazhou[11] ; Hu, Xiaoping[12] ; Lan, Jianping[13] ; Deng, Xiuzhi[14] ; Chen, Tong[15] ; Feng, Xianqi[16] ; Li, Dengju[17] ; Hou, Ming[18] ; Fu, Rong[19] ; Huang, Siyong[20] ; Wang, Jingbo[21] ; Du, Xin[7,22] ; Yang, Hui[23] ; Yang, Haiping[24] ; Jiang, Yingzhi[25] ; Wang, Zhijie[25] ; Li, Deng[25] ; Liu, Bing[25] ; Kang, Ning[25] ; Zhuang, Yulei[25] ; Zhang, Yingjun[25] ;
单位： [1]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China [2]Southeast Univ, Zhongda Hosp, Nanjing, Peoples R China [3]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [4]Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China [5]Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China [6]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China [7]Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China [8]Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China [9]Hainan Gen Hosp, Haikou, Hainan, Peoples R China [10]Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China [11]Baoji Cent Hosp, Baoji, Peoples R China [12]PKU Care Luzhong Hosp, Zibo, Peoples R China [13]Zhejiang Prov Peoples Hosp, Dept Hematol, Hangzhou, Peoples R China [14]Weihai Municipal Hosp, Weihai, Peoples R China [15]Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai, Peoples R China [16]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [17]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China [18]Shandong Univ, Qilu Hosp, Jinan, Peoples R China [19]Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China [20]Xian Gaoxin Hosp, Xian, Peoples R China [21]Aerosp Ctr Hosp, Beijing, Peoples R China [22]Second Peoples Hosp Shenzhen, Shenzhen, Peoples R China [23]Southern Med Univ, Shunde Hosp, Foshan, Peoples R China [24]Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China [25]Sunshine Lake Pharma Co Ltd, Dongguan, Peoples R China
出处：
DOI： 10.1182/blood-2023-188961
ISSN：

关键词： Acute myeloid leukemia FLT3 inhibitor Clifutinib

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 血液学
JCR分区：
出版当年[2021]版：
Q1 HEMATOLOGY
最新[2024]版：
Q1 HEMATOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Jin Jie,Wang Huafeng,Yu Wen-Juan,et al.Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study[J].BLOOD.2023,142:doi:10.1182/blood-2023-188961.
APA：
Jin, Jie,Wang, Huafeng,Yu, Wen-Juan,Ge, Zheng,Wei, Xudong...&Zhang, Yingjun.(2023).Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study.BLOOD,142,
MLA：
Jin, Jie,et al."Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study".BLOOD 142.(2023)

相关文献

[1]Homoharringtonine combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia [2]Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia [3]Case report: A rare case of acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia [4]Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia [5]Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia [6]XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway [7]急性髓系白血病中表观遗传学的研究进展 [8]Overexpression of KDM4D promotes acute myeloid leukemia cell development by activating MCL-1 [9]Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia [10]Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy

资源点击量：622 今日访问量：0 总访问量：452 更新日期：2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）